180
views
0
recommends
+1 Recommend
0 collections
    24
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      An overview of prognostic factors for long-term survivors of breast cancer

      review-article
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Numerous studies have examined prognostic factors for survival of breast cancer patients, but relatively few have dealt specifically with 10+-year survivors.

          Methods

          A review of the PubMed database from 1995 to 2006 was undertaken with the following inclusion criteria: median/mean follow-up time at least 10 years; overall survival and/or disease-specific survival known; and relative risk and statistical probability values reported. In addition, we used data from the long-standing Eindhoven Cancer Registry to illustrate survival probability as indicated by various prognostic factors.

          Results

          10-year breast cancer survivors showed 90% 5-year relative survival. Tumor size, nodal status and grade remained the most important prognostic factors for long-term survival, although their role decreased over time. Most studies agreed on the long-term prognostic values of MI (mitotic index), LVI (lymphovascular invasion), Her2-positivity, gene profiling and comorbidity for either all or a subgroup of breast cancer patients (node-positive or negative). The roles of age, socioeconomic status, histological type, BRCA and p53 mutation were mixed, often decreasing after correction for stronger prognosticators, thus limiting their clinical value. Local and regional recurrence, metastases and second cancer may substantially impair long-term survival. Healthy lifestyle was consistently related to lower overall mortality.

          Conclusions

          Effects of traditional prognostic factors persist in the long term and more recent factors need further follow-up. The prognosis for breast cancer patients who have survived at least 10 years is favourable and increases over time. Improved long-term survival can be achieved by earlier detection, more effective modern therapy and healthier lifestyle.

          Related collections

          Most cited references105

          • Record: found
          • Abstract: found
          • Article: not found

          A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

          A strong candidate for the 17q-linked BRCA1 gene, which influences susceptibility to breast and ovarian cancer, has been identified by positional cloning methods. Probable predisposing mutations have been detected in five of eight kindreds presumed to segregate BRCA1 susceptibility alleles. The mutations include an 11-base pair deletion, a 1-base pair insertion, a stop codon, a missense substitution, and an inferred regulatory mutation. The BRCA1 gene is expressed in numerous tissues, including breast and ovary, and encodes a predicted protein of 1863 amino acids. This protein contains a zinc finger domain in its amino-terminal region, but is otherwise unrelated to previously described proteins. Identification of BRCA1 should facilitate early diagnosis of breast and ovarian cancer susceptibility in some individuals as well as a better understanding of breast cancer biology.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

            The ninth St Gallen (Switzerland) expert consensus meeting in January 2005 made a fundamental change in the algorithm for selection of adjuvant systemic therapy for early breast cancer. Rather than the earlier approach commencing with risk assessment, the Panel affirmed that the first consideration was endocrine responsiveness. Three categories were acknowledged: endocrine responsive, endocrine non-responsive and tumors of uncertain endocrine responsiveness. The three categories were further divided according to menopausal status. Only then did the Panel divide patients into low-, intermediate- and high-risk categories. It agreed that axillary lymph node involvement did not automatically define high risk. Intermediate risk included both node-negative disease (if some features of the primary tumor indicated elevated risk) and patients with one to three involved lymph nodes without additional high-risk features such as HER 2/neu gene overexpression. The Panel recommended that patients be offered chemotherapy for endocrine non-responsive disease; endocrine therapy as the primary therapy for endocrine responsive disease, adding chemotherapy for some intermediate- and all high-risk groups in this category; and both chemotherapy and endocrine therapy for all patients in the uncertain endocrine response category except those in the low-risk group.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The Nottingham Prognostic Index in primary breast cancer.

              In 1982 we constructed a prognostic index for patients with primary, operable breast cancer. This index was based on a retrospective analysis of 9 factors in 387 patients. Only 3 of the factors (tumour size, stage of disease, and tumour grade) remained significant on multivariate analysis. The index was subsequently validated in a prospective study of 320 patients. We now present the results of applying this prognostic index to all of the first 1,629 patients in our series of operable breast cancer up to the age of 70. We have used the index to define three subsets of patients with different chances of dying from breast cancer: 1) good prognosis, comprising 29% of patients with 80% 15-year survival; 2) moderate prognosis, 54% of patients with 42% 15-year survival; 3) poor prognosis, 17% of patients with 13% 15-year survival. The 15-year survival of an age-matched female population was 83%.
                Bookmark

                Author and article information

                Contributors
                +31-10-4087005 , +31-10-4638474 , i.soerjomataram@erasmusmc.nl
                Journal
                Breast Cancer Res Treat
                Breast Cancer Research and Treatment
                Springer US (Boston )
                0167-6806
                1573-7217
                22 March 2007
                February 2008
                : 107
                : 3
                : 309-330
                Affiliations
                [1 ]Department of Public Health, Erasmus MC, P.O. Box 2040, Rotterdam, 3000 CA The Netherlands
                [2 ]Comprehensive Cancer Centre South, P.O. Box 231, 5600 AE Eindhoven, The Netherlands
                [3 ]Department of Radiotherapy Catharina Hospital, P.O. Box 1350, 5602 ZA Eindhoven, The Netherlands
                [4 ]Department of Surgery, St. Elisabeth Hospital, P.O. Box 90151, 5000 LC Tilburg, The Netherlands
                Article
                9556
                10.1007/s10549-007-9556-1
                2217620
                17377838
                8fd6a6aa-6c56-441e-8e81-8525b80cfc80
                © Springer Science+Business Media, LLC 2007
                History
                : 16 February 2007
                : 20 February 2007
                Categories
                Review
                Custom metadata
                © Springer Science+Business Media, LLC. 2008

                Oncology & Radiotherapy
                long-term,prognostic factors,survival,breast cancer
                Oncology & Radiotherapy
                long-term, prognostic factors, survival, breast cancer

                Comments

                Comment on this article